本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Innate Pharma SA

1.80
-0.0200-1.10%
成交量:1.83萬
成交額:3.26萬
市值:1.66億
市盈率:-2.80
高:1.84
開:1.84
低:1.75
收:1.82
52周最高:3.51
52周最低:1.29
股本:9,218.55萬
流通股本:5,922.40萬
量比:0.62
換手率:0.03%
股息:- -
股息率:- -
每股收益(TTM):-0.6440
每股收益(LYR):-0.6319
淨資產收益率:-271.37%
總資產收益率:-25.92%
市淨率:27.94
市盈率(LYR):-2.85

資料載入中...

2025/05/30

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/04/30

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/09/11

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/04/04

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/01/12

SEC問詢函

Form CORRESP - Correspondence
2023/04/20

[修訂]年度報告

20-F/A [Amend] - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/04/06

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/12/06

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/10/21

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/04/04

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/07/12

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2021/05/11

財報披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2021/04/27

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/03/16

財報披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2021/02/12

超過5%披露

SC 13D - General statement of acquisition of beneficial ownership
2021/01/27

SEC問詢函

CORRESP [Cover] - Correspondence
2020/04/24

年度報告

Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2020/04/14

非美公司披露報告

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/04/14

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/03/10

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]